Literature DB >> 11771535

Iontophoretic evaluation of vascular reactivity to acetylcholine in patients with primary Raynaud's phenomenon and systemic sclerosis.

B Marasini, L Conciato.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11771535     DOI: 10.1007/s100670170016

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  4 in total

1.  Non-invasive assessment of digital vascular reactivity in patients with primary Raynaud's phenonenon and systemic sclerosis.

Authors:  M E Anderson; F Campbell; S Hollis; T Moore; M I Jayson; A L Herrick
Journal:  Clin Exp Rheumatol       Date:  1999 Jan-Feb       Impact factor: 4.473

2.  Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon.

Authors:  F Khan; S J Litchfield; M McLaren; D J Veale; R C Littleford; J J Belch
Journal:  Arthritis Rheum       Date:  1997-02

3.  Microvascular involvement in systemic sclerosis: laser Doppler evaluation of reactivity to acetylcholine and sodium nitroprusside by iontophoresis.

Authors:  L La Civita; M Rossi; G Vagheggini; F A Storino; L Credidio; G Pasero; C Giusti; C Ferri
Journal:  Ann Rheum Dis       Date:  1998-01       Impact factor: 19.103

4.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05
  4 in total
  2 in total

Review 1.  A vascular mechanistic approach to understanding Raynaud phenomenon.

Authors:  Nicholas A Flavahan
Journal:  Nat Rev Rheumatol       Date:  2014-12-23       Impact factor: 20.543

2.  No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis.

Authors:  Martha E Hettema; Dan Zhang; Ymkje Stienstra; Andries J Smit; Hendrika Bootsma; Cees G M Kallenberg
Journal:  Clin Rheumatol       Date:  2009-04-07       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.